Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
NCT06133231 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2025-01-16
Summary
Evaluate feasibility and acceptability of recruiting Black and Hispanic families for an open label clinical trial of multinutrients while collecting real-time parent-reported child behavior data and collecting at-home biospecimens to explore their potential as biomarkers, in a study of pediatric ADHD.
Conditions
- Attention Deficit/Hyperactivity Disorder
- Emotional Dysfunction
- Irritable Mood
Interventions
- DIETARY_SUPPLEMENT
-
Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
Participants will take 2-4 capsules of EMP+ Advanced per day (max 8 capsules) for eight weeks.
Sponsors & Collaborators
-
Oregon Health and Science University
lead OTHER
Principal Investigators
-
Jeanette Johnstone, PhD · Oregon Health and Science University
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 6 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-06
- Primary Completion
- 2025-09-30
- Completion
- 2026-01-31
Countries
- United States
Study Locations
More Related Trials
-
Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication
NCT00561340 ·Status: COMPLETED ·Phase: NA
-
Dietary Intake and Nutrient Status of Children With ADHD
NCT00434928 ·Status: COMPLETED
-
Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)
NCT01069523 ·Status: COMPLETED ·Phase: PHASE4
-
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
NCT00050622 ·Status: COMPLETED ·Phase: NA
-
Omega-3 Supplementation to ADHD Medication in Children
NCT02204410 ·Status: COMPLETED ·Phase: PHASE4
-
Treating Young Children With Attention Deficit Hyperactivity Disorder
NCT07300956 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Cost-effectiveness of the Treatment of Attention Deficit/Hyperactivity Disorder With Methylphenidate Immediate-release in Brazil
NCT01705613 ·Status: COMPLETED
-
Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder
NCT00301236 ·Status: COMPLETED ·Phase: PHASE3
-
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
NCT01399827 ·Status: COMPLETED ·Phase: PHASE2
-
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
NCT00183391 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit Hyperactivity Disorder (ADHD)
NCT01022229 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
NCT01081132 ·Status: COMPLETED ·Phase: PHASE3
-
Leveraging Mobile Health Technology to Optimize Early Stimulant Medication Treatment: A Feasibility Pilot
NCT01990222 ·Status: COMPLETED
-
The Role of Adverse Environment Factors, Family Functioning and Parental Psychopathology in the Response to Treatment With Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder
NCT00773916 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
NCT00483106 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate
NCT00931398 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effectiveness of a Behavioral Treatment Program for Attention Deficit Hyperactivity Disorder, Inattentive Type
NCT00834821 ·Status: COMPLETED ·Phase: NA
-
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
NCT01330693 ·Status: UNKNOWN ·Phase: PHASE3
-
Stimulant Drug Treatment of Attention-Deficit Hyperactivity Disorder (AD/HD), Inattentive Type
NCT00824317 ·Status: COMPLETED ·Phase: NA
-
Event Rate and Effects of Stimulants in ADHD
NCT01913912 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)
NCT01472991 ·Status: COMPLETED ·Phase: PHASE2
-
ADHD Medication and Predictors of Treatment Outcome
NCT02136147 ·Status: COMPLETED
-
Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD
NCT00214981 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder
NCT00518232 ·Status: COMPLETED ·Phase: PHASE4
-
Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)
NCT00862108 ·Status: UNKNOWN ·Phase: PHASE4